Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 6, Number 6—December 2000
Perspective

Evidence Against Rapid Emergence of Praziquantel Resistance in Schistosoma haematobium, Kenya

Charles H. King*, Eric M. Muchiri†, and John H. Ouma†
Author affiliations: *Case Western Reserve University School of Medicine and University Hospitals of Cleveland, Cleveland, Ohio, USA; †Ministry of Health, Nairobi, Kenya

Main Article

Table 2

Schistosoma haematobium, Coast Province, Kenya, and elsewhere in Africa

Site Cure rate(s) observed (%) Year(s) Reference
Coast Province, Kenya
Kajiwe, Kilifi district 62-65 1994 Olds et al., 45
Msambweni area, Kwale district 65-96 1984-91 present study
Southern Kwale district 84 1986 King et al., 46
Kwale district 87 1986 Stephenson et al., 47
Elsewhere
Senegal 80-93 1995 Shaw et al., 48
Ghana 67 1994 Chan et al., 9
Zimbabwe 72 1986 Taylor et al, 49
Mauritania 90-95 1985-86 Etard et al., 50
Ghana 60 1984 Mott et al., 42
Egypt 59-62 1983 el Malatawy et al., 51
Gambia 57-93 1983 Wilkins et al., 52
Tanzania 66-83 1979 McMahon and Kolstrup, 53

Main Article

References
  1. World Health Organization. The control of schistosomiasis: second report of the WHO Expert Committee. Vol. 830 Geneva: 1993 WHO Technical Report.
  2. Drugs for parasitic infections. Med Lett Drugs Ther. 1998;40:1–12.PubMedGoogle Scholar
  3. Hotez  PJ, Zheng  F, Long-qi  X, Ming-gang  C, Shu-hua  X, Shu-xian  L, Emerging and reemerging helminthiases and the public health of China. Emerg Infect Dis. 1997;3:303–10. DOIPubMedGoogle Scholar
  4. Praziquantel. USP Drug Information. Vol. I. Rockville (MD): United States Pharmacopeial Convention; 1998:2395-7.
  5. King  CH, Mahmoud  AA. Drugs five years later: praziquantel. Ann Intern Med. 1989;110:290–6.PubMedGoogle Scholar
  6. Davis  A, Wegner  DH. Multicentre trials of praziquantel in human schistosomiasis: design and techniques. Bull World Health Organ. 1979;57:767–71.PubMedGoogle Scholar
  7. Brindley  PJ. Drug resistance to schistosomicides and other anthelmintics of medical significance. Acta Trop. 1994;56:213–31. DOIPubMedGoogle Scholar
  8. Boisier  P, Ramarokoto  CE, Ravaoalimalala  VE, Rabarijaona  L, Serieye  J, Roux  J, Reversibility of Schistosoma mansoni-associated morbidity after yearly mass praziquantel therapy: ultrasonographic assessment. Trans R Soc Trop Med Hyg. 1998;92:451–3. DOIPubMedGoogle Scholar
  9. Chan  MS, Nsowah-Nuamah  NNN, Adjei  S, Wen  S, Hall  A, Bundy  DAP. Predicting impact of school-based treatment for urinary schistosomiasis given by the Ghana Partnership for Child Development. Trans R Soc Trop Med Hyg. 1998;92:386–9. DOIPubMedGoogle Scholar
  10. Jongsuksuntigul  P, Imsomboon  T. The impact of a decade long opisthorchiasis control program in northeastern Thailand. Southeast Asian J Trop Med Public Health. 1997;28:551–7.PubMedGoogle Scholar
  11. Schelling  U, Frank  W, Will  R, Romig  T, Lucius  R. Chemotherapy with praziquantel has the potential to reduce the prevalence of Echinococcus multilocularis in wild foxes (Vulpes vulpes). Ann Trop Med Parasitol. 1997;91:179–86.PubMedGoogle Scholar
  12. Llayd  S, Walters  TM. Worming of dogs in mid-Wales for Echinococcus granulosus. Vet Rec. 1997;140:487–8.PubMedGoogle Scholar
  13. Olveda  RM, Daniel  BL, Ramirez  BD, Aligui  GD, Acosta  LP, Fevidal  P, Schistosomiasis japonica in the Philippines: the long-term impact of population-based chemotherapy on infection, transmission, and morbidity. J Infect Dis. 1996;174:163–72.PubMedGoogle Scholar
  14. Renganathan  E, Cioli  D. An international initiative on praziquantel use. Parasitol Today. 1998;14:390–1. DOIPubMedGoogle Scholar
  15. Kusel  J, Hagan  P. Praziquantel--its use, cost and possible development of resistance [news]. Parasitol Today. 1999;15:352–4. DOIPubMedGoogle Scholar
  16. Guisse  F, Polman  K, Stelma  FF, Mbaye  A, Talla  I, Niang  M, Therapeutic evaluation of two different dose regimens of praziquantel in a recent Schistosoma mansoni focus in Northern Senegal. Am J Trop Med Hyg. 1997;56:511–4.PubMedGoogle Scholar
  17. Stelma  FF, Sall  S, Daff  B, Sow  S, Niang  M, Gryseels  B. Oxamniquine cures Schistosoma mansoni infection in a focus in which cure rates with praziquantel are unusually low. J Infect Dis. 1997;176:304–7. DOIPubMedGoogle Scholar
  18. Stelma  FF, Talla  I, Sow  S, Kongs  A, Niang  M, Polman  K, Efficacy and side effects of praziquantel in an epidemic focus of Schistosoma mansoni. Am J Trop Med Hyg. 1995;53:167–70.PubMedGoogle Scholar
  19. Picquet  M, Vercruysse  J, Shaw  DJ, Diop  M, Ly  A. Efficacy of praziquantel against Schistosoma mansoni in northern Senegal. Trans R Soc Trop Med Hyg. 1998;92:90–3. DOIPubMedGoogle Scholar
  20. Bennett  JL, Day  T, Feng-Tao  L, Ismail  M, Farghaly  A. The development of resistance to anthelmintics: A perspective with an emphasis on the antischistosomal drug praziquantel. Exp Parasitol. 1997;87:260–7. DOIPubMedGoogle Scholar
  21. Fallon  PG, Mubarak  JS, Fookes  RE, Niang  M, Butterworth  AE, Sturrock  RF, Schistosoma mansoni: maturation rate and drug susceptibility of different geographic isolates. Exp Parasitol. 1997;86:29–36. DOIPubMedGoogle Scholar
  22. Pereira  C, Fallon  PG, Cornette  J, Capron  A, Doenhoff  MJ, Pierce  RJ. Alterations in cytochrome-c oxidase expression between praziquantel-resistant and susceptible strains of Schistosoma mansoni. Parasitology. 1998;117:63–73. DOIPubMedGoogle Scholar
  23. Cunha  VM, Noel  F. (Ca(2+)-Mg2+)ATPase in Schistosoma mansoni: evidence for heterogeneity and resistance to praziquantel. Mem Inst Oswaldo Cruz. 1998;93:181–2. DOIPubMedGoogle Scholar
  24. Cioli  D, Pica Mattoccia  L. Genetic analysis of hycanthone resistance in Schistosoma mansoni. Am J Trop Med Hyg. 1984;33:80–8.PubMedGoogle Scholar
  25. King  CH, Lombardi  G, Lombardi  C, Greenblatt  R, Hodder  S, Kinyanjui  H, Chemotherapy-based control of schistosomiasis haematobia. I. Metrifonate versus praziquantel in control of intensity and prevalence of infection. Am J Trop Med Hyg. 1988;39:295–305.PubMedGoogle Scholar
  26. King  CH, Muchiri  EM, Ouma  JH. Age-targeted chemotherapy for control of urinary schistosomiasis in endemic populations. Mem Inst Oswaldo Cruz. 1992;87:203–10. DOIPubMedGoogle Scholar
  27. Muchiri  EM, Ouma  JH, King  CH. Dynamics and control of Schistosoma haematobium transmission in Kenya: an overview of the Msambweni Project. Am J Trop Med Hyg. 1996;55:127–34.PubMedGoogle Scholar
  28. Khoury  MJ, Beaty  TH, Cohen  BH. Fundamentals of genetic epidemiology. New York: Oxford University Press; 1993.
  29. Anderson  RM, May  RM. Infectious diseases of humans: dynamics and control. New York: Oxford University Press; 1991. pp. 467-96; 507-20.
  30. Sturrock  RF, Kinyanjui  H, Thiongo  FW, Tosha  S, Ouma  JH, King  CH, Chemotherapy-based control of schistosomiasis haematobia. 3. Snail studies monitoring the effect of chemotherapy on transmission in the Msambweni area, Kenya. Trans R Soc Trop Med Hyg. 1990;84:257–61. DOIPubMedGoogle Scholar
  31. Muchiri  EM. Association of water contact activities and risk of reinfection for S. haematobium after drug treatment in the Msambweni Area, Kenya [MS thesis, Epidemiology and Biostatistics]. Cleveland (OH): Case Western Reserve University; 1991.
  32. Ismail  M, Metwally  A, Farghaly  A, Bruce  J, Tao  LF, Bennett  JL. Characterization of isolates of Schistosoma mansoni from Egyptian villagers that tolerate high doses of praziquantel. Am J Trop Med Hyg. 1996;55:214–8.PubMedGoogle Scholar
  33. Fallon  PG, Sturrock  RF, Niang  AC, Doenhoff  MJ. Short report: diminished susceptibility to praziquantel in a Senegal isolate of Schistosoma mansoni. Am J Trop Med Hyg. 1995;53:61–2.PubMedGoogle Scholar
  34. Fallon  PG, Doenhoff  MJ. Drug-resistant schistosomiasis: resistance to praziquantel and oxamniquine induced in Schistosoma mansoni in mice is drug specific. Am J Trop Med Hyg. 1994;51:83–8.PubMedGoogle Scholar
  35. Laurent  C, Lamothe  F, Develoux  M, Sellin  B, Mouchet  F. Ultrasonographic assessment of urinary tract lesions due to Schistosoma haematobium in Niger after four consecutive years of treatment with praziquantel. Trop Med Parasitol. 1990;41:139–42.PubMedGoogle Scholar
  36. Rainey  BP, Moxon  ER. Microbiology. When being hyper keeps you fit. Science. 2000;288:1186–7. DOIPubMedGoogle Scholar
  37. Field  D, Magnasco  MO, Moxon  ER, Metzgar  D, Tanaka  MM, Wills  C, Contingency loci, mutator alleles, and their interactions. Synergistic strategies for microbial evolution and adaptation in pathogenesis. Ann N Y Acad Sci. 1999;870:378–82. DOIPubMedGoogle Scholar
  38. Moxon  ER, Rainey  PB, Nowak  MA, Lenski  RE. Adaptive evolution of highly mutable loci in pathogenic bacteria. Curr Biol. 1994;4:24–33. DOIPubMedGoogle Scholar
  39. Caporale  LH. Chance favors the prepared genome. Ann N Y Acad Sci. 1999;870:1–21. DOIPubMedGoogle Scholar
  40. Drake  JW. The distribution of rates of spontaneous mutation over viruses, prokaryotes, and eukaryotes. Ann N Y Acad Sci. 1999;870:100–7. DOIPubMedGoogle Scholar
  41. Davis  A, Biles  JE, Ulrich  AM. Initial experiences with praziquantel in the treatment of human infections due to Schistosoma haematobium. Bull World Health Organ. 1979;57:773–9.PubMedGoogle Scholar
  42. Mott  KE, Dixon  H, Osei-Tutu  E, England  EC, Davis  A. Effect of praziquantel on hematuria and proteinuria in urinary schistosomiasis. Am J Trop Med Hyg. 1985;34:1119–26.PubMedGoogle Scholar
  43. Stephenson  LS, Latham  MC, Kinoti  SN, Oduori  ML. Sensitivity and specificity of reagent strips in screening of Kenyan children for Schistosoma haematobium infection. Am J Trop Med Hyg. 1984;33:862–71.PubMedGoogle Scholar
  44. Pugh  RN, Bell  DR, Gilles  HM. Malumfashi Endemic Diseases Research Project, XV. The potential medical importance of bilharzia in northern Nigeria: a suggested rapid, cheap and effective solution for control of Schistosoma haematobium infection. Ann Trop Med Parasitol. 1980;74:597–613.PubMedGoogle Scholar
  45. Olds  GR, King  CH, Hewlett  J, Olveda  R, Wu  G, Ouma  JH, Double-blind placebo controlled study of concurrent administration of albendazole and praziquantel in school children with schistosomiasis and geohelminths. J Infect Dis. 1999;179:996–1003. DOIPubMedGoogle Scholar
  46. King  CH, Wiper  DWD, De Stigter  KV, Peters  PA, Koech  D, Ouma  JH, . Dose-finding study for praziquantel therapy of Schistosoma haematobium in Coast Province, Kenya. Am J Trop Med Hyg. 1989;40:507–13.PubMedGoogle Scholar
  47. Stephenson  LS, Latham  MC, Kurz  KM, Kinoti  SN. Single dose metrifonate or praziquantel treatment in Kenyan children. II. Effects on growth in relation to Schistosoma haematobium and hookworm egg counts. Am J Trop Med Hyg. 1989;41:445–53.PubMedGoogle Scholar
  48. Shaw  DJ, Vercruysse  J, Picquet  M, Sambou  B, Ly  A. The effect of different treatment regimens on the epidemiology of seasonally transmitted Schistosoma haematobium infections in four villages in the Senegal River Basin, Senegal. Trans R Soc Trop Med Hyg. 1999;93:142–50. DOIPubMedGoogle Scholar
  49. Taylor  P, Murare  HM, Manomano  K. Efficacy of low doses of praziquantel for Schistosoma mansoni and S. haematobium. J Trop Med Hyg. 1988;91:13–7.PubMedGoogle Scholar
  50. Etard  JF, Borel  E, Segala  C. Schistosoma haematobium infection in Mauritania: two years of follow-up after a targeted chemotherapy--a life-table approach of the risk of reinfection. Parasitology. 1990;100:399–406. DOIPubMedGoogle Scholar
  51. el Malatawy  A, el Habashy  A, Lechine  N, Dixon  H, Davis  A, Mott  KE. Selective population chemotherapy among schoolchildren in Beheira governorate: the UNICEF/Arab Republic of Egypt/WHO Schistosomiasis Control Project. Bull World Health Organ. 1992;70:47–56.PubMedGoogle Scholar
  52. Wilkins  HA, Blumenthal  UJ, Hayes  RJ, Tulloch  S. Resistance to reinfection after treatment of urinary schistosomiasis. Trans R Soc Trop Med. 1987;81:29–35. DOIPubMedGoogle Scholar
  53. McMahon  JE, Kolstrup  N. Praziquantel: a new schistosomicide against Schistosoma haematobium. BMJ. 1979;2:1396–8. DOIPubMedGoogle Scholar

Main Article

Page created: December 17, 2010
Page updated: December 17, 2010
Page reviewed: December 17, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external